Drug cross-resistance and therapy-induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing.

Drug cross-resistance and therapy-induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing.

Previous results with individualised tumour response testing (ITRT) in vitro in chronic lymphocytic leukaemia (CLL) have consistently shown good correlation with patient response and survival. We describe here an improved test and report its use with samples from the Leukaemia Research Fund CLL4 ran...

Full description

Bibliographic Details
Main Authors:	Bosanquet, A, Richards, S, Wade, R, Else, M, Matutes, E, Dyer, M, Rassam, S, Durant, J, Scadding, S, Raper, S, Dearden, C, Catovsky, D
Format:	Journal article
Language:	English
Published:	2009

Similar Items

Drug sensitivity by TRAC (DISC) assay as a prognostic factor for patient response in untreated CLL: Results from the UK LRF CLL4 trial.
by: Bosanquet, A, et al.
Published: (2006)

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.
by: Catovsky, D, et al.
Published: (2007)

The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry.
by: Matutes, E, et al.
Published: (2013)

The use of individualized tumor response testing in treatment selection: Second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry
by: Matutes, E, et al.
Published: (2013)

Patients' experience of chronic lymphocytic leukaemia: baseline health-related quality of life results from the LRF CLL4 trial.
by: Else, M, et al.
Published: (2008)

Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay.
by: Bosanquet, A, et al.
Published: (1999)

Fludarabine plus cyclophosphamide induces better response rates and progression-free survival across all age and risk groups in the LRF CLL4 trial (on behalf of the UKNCRI CLL Trials Group)
by: Catovsky, D, et al.
Published: (2006)

The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia.
by: Dearden, C, et al.
Published: (2008)

A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial.
by: Dearden, C, et al.
Published: (2011)

The combination of fludarabine and cyclophosphamide has a beneficial effect on the incidence of hemolytic anemia in chronic lymphocytic leukemia. Results from the UK LRF CLL4 trial
by: Dearden, C, et al.
Published: (2007)

Preliminary results of the UK Medical Research Council trial in chronic lymphocytic leukaemia - CLL3
by: Catovsky, D, et al.
Published: (1998)

miRNAs in Lymphocytic Leukaemias—The miRror of Drug Resistance
by: Yordan Sbirkov, et al.
Published: (2022-04-01)

Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults.
by: Catovsky, D, et al.
Published: (1989)

The clinical significance of patients' sex in chronic lymphocytic leukemia.
by: Catovsky, D, et al.
Published: (2014)

Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia.
by: Oscier, D, et al.
Published: (2012)

Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.
by: Gonzalez, D, et al.
Published: (2011)

The distribution of CD45R, CD29 and CD45RO (UCHL1) antigens in mature CD4 positive T-cell leukaemias.
by: Worner, I, et al.
Published: (1990)

Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial.
by: Else, M, et al.
Published: (2012)

Individualising radiation therapy decisions in breast cancer patients based on tumour infiltrating lymphocytes and genomic biomarkers
by: Melanie Machiels, et al.
Published: (2023-10-01)

Prognostic significance of membrane antigens and morphology in chronic lymphocytic leukemia.
by: Matutes, E, et al.
Published: (1999)

Collaborative meta-analysis of randomised trials in chronic lymphocytic leukaemia (CLL)
by: Binet, J, et al.
Published: (1998)

Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation.
by: Oscier, D, et al.
Published: (2010)

Individualising therapy for drug-sensitive tuberculosis
by: Esmail, H, et al.
Published: (2019)

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition
by: Lander, Eric Steven
Published: (2017)

Will New Drugs Replace Transplants for Chronic Lymphocytic Leukaemia?
by: Shenmiao Yang, et al.
Published: (2021-06-01)

Impact of binet staging versus tumour bulk on treatment outcome in chronic lymphocytic leukaemia
by: Anazoeze Jude Madu, et al.
Published: (2024-01-01)

Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia
by: Paul Yeh, et al.
Published: (2017-03-01)

Individualising drug dispensaries in a university hospital
by: M Jordan, et al.
Published: (2007-01-01)

Thymic epithelial tumours: from basic principles to individualised treatment strategies
by: Nicolas Girard
Published: (2013-03-01)

Paraspinal tumour deposits in chronic lymphocytic leukaemia – A rare presentation: Case report and literature review
by: S Ocheni, et al.
Published: (2012-01-01)

Response to therapy and survival in CLL is influenced by genetic markers. preliminary analysis from the LRF CLL4 trial.
by: Catovsky, D, et al.
Published: (2004)

Individualised treatment for multidrug‐resistant tuberculosis in New South Wales, Australia
by: Vicky Chang, et al.
Published: (2021-10-01)

Mutational Status of the TP53 Gene as a Predictor of Response and Survival in CLL Patients with and without 17p Deletion
by: Gonzalez, D, et al.
Published: (2008)

HEMATOLOGICAL MALIGNANCIES. LYMPHOCYTIC LEUKAEMIA
by: Peter F. Litvitsky, et al.
Published: (2016-11-01)

Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry
by: Ferenc Takács, et al.
Published: (2022-09-01)

P598: EBI3/IL-27 DEPLETED MICROENVIRONMENT FAVOURS TUMOUR PROGRESSION IN CHRONIC LYMPHOCYTIC LEUKAEMIA
by: I. C. Botana, et al.
Published: (2022-06-01)

High mortality of DiSC assay-resistant CLL patients treated with fludarabine.
by: Bosanquet, A, et al.
Published: (1998)

Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model
by: Claudia Christowitz, et al.
Published: (2019-08-01)

Combination strategies to overcome drug resistance in FLT+ acute myeloid leukaemia
by: Jingmei Yang, et al.
Published: (2023-08-01)

Characterizing drug resistance in hypoxia-adapted chronic myeloid leukaemia cells.
by: Muhammad Rauzan Rafman.
Published: (2013)